_256_384.jpg)
Tirzepatide is a prescription based the first and only dual agonist of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors
Yesintek and Yesintek I.V. are approved for the treatment of moderate to severe plaque psoriasis in adults and pediatric patients
Gazyva/Gazyvaro is the only anti-CD20 monoclonal antibody to demonstrate a complete renal response benefit in lupus nephritis in a randomised phase III study
Accelerating hit-to-lead timelines, and strengthening end-to-end drug discovery and development services
Cadila Pharmaceuticals has introduced Dlorfast-M-Tablets as a dual-action therapy that targets two key pathways of allergic response
AstraZeneca to invest $50bn in manufacturing and R&D to support domestic sourcing
Acquisition expands Novo Nordisk’s leadership in obesity-related comorbidities and metabolic diseases
The company will present new data from across over 20 cancer types and multiple treatment settings at European Society for Medical Oncology Congress 2025
New gene expression profiling test enhances precision in assessing lung transplant rejection and injury
Positive volume growth was observed in key therapies such as respiratory (13.2% yoy), anti-neoplastics (12.1% yoy) and cardiac (4.8% yoy) during September 2025
Subscribe To Our Newsletter & Stay Updated
